血浆溶血磷脂酸和癌抗原125检测在卵巢癌早期诊断中的价值  

Early diagnosis value in of serum lysophosphatidic acid and CA-125 detection ovarian cancer

作　　者：周凤珍[1] 罗璐[1] 

机构地区：[1]深圳市第二人民医院妇产科,广东省深圳518029

出　　处：《中国基层医药》2009年第12期2117-2118,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨血浆溶血磷脂酸（LPA）和CA-125检测在卵巢癌早期诊断中的价值。方法选取2005年10月至2008年2月收治的卵巢癌患者50例为卵巢癌组，同时选取同期卵巢良性肿瘤患者44例（卵巢良性病组），以及50例健康妇女作为健康对照组，全部病例均于术前采血且经病理诊断证实，分别检测各组血浆LPA和CA-125。结果血浆LPA水平在卵巢癌组中的均值及阳性率明显高于卵巢良性病组和健康对照组（P〈0．05），血浆CA-125在卵巢癌组中的均值和阳性率与卵巢良性病组相比较差异无统计学意义（P〉0．05），但两组均高于健康对照组（P〈0．05）；血浆LPA检测特异度明显高于血浆CA．125检测，早期卵巢癌的诊断中，两者联合检测的灵敏度为85．7％，优于单项检测（P〈0．01）；Ⅱ-Ⅳ期卵巢癌患者血浆LPA及CA-125阳性率及水平较Ⅰ期高（P〈0．01）；CA-125阳性率在卵巢癌各病理类型间比较差异有统计学意义（P〈0．05）。结论LPA是卵巢上皮性癌的诊断尤其是早期诊断的敏感生物学标记物，联合检测CA-125可提高卵巢癌的早期诊断率。Objective To explore the clinical value of early diagnosis of ovarian cancer by serum lysophos- phatidic acid（LPA） and CA-125. Methods 50 patients with ovarian cancer from October 2005 to February 2008 were selected as ovarian cancer group, at the same period selected 44 patients with ovarian benign tumor（ ovarian benign disease group） ,and 50 healthy women as the healthy control group. All patients were diagnosed and confirmed by preoperative blood and pathology. The serum LPA and CA-125 of two groups were detected. Results The serum LPA level and the positive rate in the ovarian cancer group was higher than that of the ovaries benign group or the control group（P 〈 0. 05）. The CA-125 level in the ovarian cancer group was similar to that of the ovaries benign group（ P 〉 0. 05 ） ,while the CA-125 level in the ovarian cancer group or the ovaries benign group was higher than that of the con- trol group（ P 〈 0. 05）. The specificity of the LPA was better than that of the CA-125 detection. In the early diagnosis of ovarian cancer,the sensitivity of the combination（ 85.7% ） was better than either of them（ P 〈 0. 01 ） ; the plasma LPA level and positive rate of CA-125 of the phase Ⅱ -Ⅳ ovarian cancer patients were higher than that of phase Ⅰ （ P 〈 0. 01 ） ;the CA-125 positive rate of the serious cystadenocarcinoma was higher than that of the eystadenocarcinoma（ P 〈0. 01 ）. Conclusion LPA is a sensitive biomarker for the early diagnosis of ovarian cancer,especially com- bined with CA-125. It should be widely used in clinic.

关 键 词：卵巢肿瘤 溶血磷脂酸类 癌抗原 

分 类 号：R737.31[医药卫生—肿瘤]